Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jose L Alonso-Romero"'
Autor:
Luis de la Cruz-Merino, María Gion, Josefina Cruz-Jurado, Vanesa Quiroga, Raquel Andrés, Fernando Moreno, Jose L. Alonso-Romero, Manuel Ramos, Esther Holgado, Javier Cortés, Elena López-Miranda, Fernando Henao-Carrasco, Natalia Palazón-Carrión, Luz M. Rodríguez, Isaac Ceballos, Maribel Casas, Sara Benito, Massimo Chiesa, Susana Bezares, Rosalia Caballero, Carlos Jiménez-Cortegana, Víctor Sánchez-Margalet, Federico Rojo
Publikováno v:
Cancers, Vol 13, Iss 21, p 5432 (2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab
Externí odkaz:
https://doaj.org/article/f493f8a297a3479694a4af97c2b66c7c
Autor:
Dennis Slamon, E. Jane Leonard, Sylvie Vincent, Kevin Galinsky, Rachel Neuwirth, Jingjing Chen, Eva Carrasco, Antonio Antón, Jose L. Alonso-Romero, Manuel Ramos, Nieves Ferrer, Santiago González-Santiago, Ainhara Lahuerta, Yolanda Jerez, Ricardo Cubedo, Noelia Martínez-Jáñez, José Á. García-Sáenz
Purpose:This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant.Patients and Methods:Postmenopausal women with estrogen receptor–positive (ER+)/HER2-negati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630979ea079a2e71f3253cb232b8dad2
https://doi.org/10.1158/1078-0432.c.6531135
https://doi.org/10.1158/1078-0432.c.6531135
Autor:
Dennis Slamon, E. Jane Leonard, Sylvie Vincent, Kevin Galinsky, Rachel Neuwirth, Jingjing Chen, Eva Carrasco, Antonio Antón, Jose L. Alonso-Romero, Manuel Ramos, Nieves Ferrer, Santiago González-Santiago, Ainhara Lahuerta, Yolanda Jerez, Ricardo Cubedo, Noelia Martínez-Jáñez, José Á. García-Sáenz
Supplementary Figure from Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030af923744a0f4a65becbf504ff188d
https://doi.org/10.1158/1078-0432.22483416
https://doi.org/10.1158/1078-0432.22483416
Autor:
Rosalia Caballero, Maribel Casas, Fernando Moreno, Massimo Chiesa, Natalia Palazón-Carrión, María Gion, Manuel Ramos, Javier Cortes, Josefina Cruz-Jurado, Isaac Ceballos, Raquel Andrés, Víctor Sánchez-Margalet, Jose L Alonso-Romero, Luis de la Cruz-Merino, Federico Rojo, Fernando Henao-Carrasco, Luz Milva Rodriguez Rodriguez, Elena López-Miranda, Esther Holgado, Vanesa Quiroga, Susana Bezares, Sara Benito, Carlos Jiménez-Cortegana
Publikováno v:
Scientia
Cancers
Volume 13
Issue 21
Cancers, Vol 13, Iss 5432, p 5432 (2021)
Cancers
Volume 13
Issue 21
Cancers, Vol 13, Iss 5432, p 5432 (2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab
Autor:
José Á. García-Sáenz, Noelia Martínez-Jáñez, Ricardo Cubedo, Yolanda Jerez, Ainhara Lahuerta, Santiago González-Santiago, Nieves Ferrer, Manuel Ramos, Jose L. Alonso-Romero, Antonio Antón, Eva Carrasco, Jingjing Chen, Rachel Neuwirth, Kevin Galinsky, Sylvie Vincent, E. Jane Leonard, Dennis Slamon
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(6)
Purpose: This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant. Patients and Methods: Postmenopausal women with estrogen receptor–positive (ER+)/HER2-neg